Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
GILD News
If you are standing at the crossroads, trying to decide what to do with Gilead Sciences stock, you are in good company. This biotech giant has made impressive m...
Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs L...
Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats for two years. RBC Capit...
Analyst ratings
70%
of 30 ratingsMore GILD News
Gilead Sciences (NASDAQ:GILD) has reached settlement agreements with Lupin, Cipla, and Laurus Labs to resolve patent disputes related to Biktarvy, a medication...
In a regulatory filing, Gilead (GILD) Sciences disclosed that on October 6, Gilead announced that it has entered into settlement agreements to resolve the paten...
On September 22, Kymera Therapeutics announced an exclusive collaboration with Gilead Sciences to develop a new molecular glue degrader program for oncology, sh...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences yesterday and set a price target of $143.00. Elevate Your Investing Strategy: Ta...